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Immunotherapies for COVID-19: lessons learned from sepsis
Therapeutic approaches to mitigate the severe acute
lung injury associated with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection have
rapidly entered clinical trials primarily on anecdotal
observations and few clinical studies. Along with the
clinical symptoms related to viral invasion, the reported
molecular response known as the cytokine storm has
attracted the greatest attention, in both the scientific and
the lay press, as a cause of organ injury. The hypothesis
that quelling this storm with anti-inflammatory therapies
directed at reducing interleukin-6 (IL-6), IL-1, or even
tumour necrosis factor α (TNFα) might be beneficial has
led to several ongoing trials. Anecdotal evidence from
non-controlled clinical trials has suggested a possible
beneficial effect, and anti-IL-6 has been shown to be
effective in chimeric antigen receptor T (CAR-T) and
cytokine response syndrome (CRS).1,2 However, past
attempts in randomised clinical trials to block the cytokine
storm associated with other microbial infections and with
sepsis have not been successful and, in some cases, have
worsened outcomes.3,4 Redundancy of cytokine action,
delayed intervention, and the essential role of these
cytokines in recovery and immune surveillance have all
been proposed as possible explanations for these findings.
The first reports from China emphasised elevated
plasma concentrations of IL-6 and provided a rationale
for the introduction of anti-IL-6 therapies (tocilizumab
and sarulimab) in randomised clinical trials.5,6 However,
closer examination of plasma IL-6 concentrations has
provided conflicting data. Results from early studies
suggested that plasma IL-6 concentrations, although
elevated (hundreds of picograms per µL) above values
obtained from healthy control patients, were modest,
especially when compared with the cytokine storm
associated with septic shock, in which concentrations
might be in the high hundreds to thousands of picograms
per µL. Although more recent controlled studies indicate
that plasma IL-6 concentrations can be in the range
seen in bacterial infections, the time course of change is
very different; in some cases, concentrations in patients
with coronavirus disease 2019 (COVID-19) seem to
increase over time with illness severity and worsening
lung function.6 These dynamics clearly distinguish the
SARS-CoV-2 host response from that seen in sepsis.
Additionally, previous sepsis studies established that

IL-6 concentrations might be an indicator of the
magnitude of the inflammatory response rather than
the cause of organ injury.7 Therefore, it is important to
ask whether current therapeutic approaches are only
targeting symptoms or are modulating the disease itself.
Little is known about the concentrations of other
proinflammatory or anti-inflammatory mediators in
patients with COVID-19, the landscape of the cytokine
storm, and especially the chemokines that regulate the
distribution and activity of effector cell populations.
Interpreting changes in cytokine concentrations—all
seem to be elevated—without additional immune
cellular parameters does not provide clarity about the
molecular basis of COVID-19 or potential treatment
strategies. Indeed, when measured in patients infected
with SARS-CoV-2, IL-10 concentrations (the most
immunosuppressant cytokine in the body) are also
elevated, which might lead to a different conclusion
for therapeutic approaches and in understanding the
disease pathophysiology. Similarly, there is concern
that suppressing the innate and adaptive immune
system to address increased cytokine concentrations,
such as elevated IL-6, could enable unfettered viral
replication, suppress adaptive immunity, and delay
recovery processes.
Lost in the current enthusiasm for anti-inflammatory
approaches to SARS-CoV-2 infection is the growing
recognition that potent immunosuppressive mech
anisms are also prevalent in such patients. This focus
is reminiscent of that seen in the early investigations
of sepsis-induced inflammation, since it was nearly
a decade later that the contribution of immune
suppression to sepsis pathology was generally accepted.
Profound lymphopenia (low absolute lymphocyte
counts, ALC), often to levels seen in septic shock, is
a near uniform finding in severely ill patients with
COVID-19 and correlates with increased secondary
infections and mortality.8,9 This loss of immune effector
cells occurs in all lymphocyte subsets, including CD8+
and natural killer cells, which have important antiviral
roles, and B cells, which are essential for making
antibodies that inactivate the virus.10–12 Autopsy results
have revealed a near complete dissolution of some
secondary lymphoid organs.13 Unsurprisingly, secondary
nosocomial infections, often with pathogens usually
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Figure: Immunological landscape in polymicrobial sepsis (A) and COVID-19 (B)
Bullet points refer to the symptoms seen throughout disease progression.
MOF=multiorgan failure. COVID-19=coronavirus disease 19. MDSC=myeloidderived suppressor cells. HLA-DR=human leukocyte antigen-DR. sPD-L1=soluble
programmed cell death protein 1.

associated with immune suppression, are present in up
to 50% of hospitalised patients.8
This early immunological picture of SARS-CoV-2
infection is one that shares many similarities with
bacterial sepsis, but some unique differences should be
noted (figure). In particular, the modest inflammatory
response and the progressive and profound suppression
of adaptive immunity in COVID-19 relative to sepsis
argues for perhaps a different therapeutic approach.
Supporting host protective immunity must be
considered as an essential component of any therapeutic
intervention, of equal importance to or perhaps greater
importance than targeting the cytokine storm.
What is the most rational approach to supporting
host protective immunity? Several immune stimulants
in the clinical armamentarium are available for patients
infected with SARS-CoV-2. Focusing on agents that
2

target adaptive immunity in general, and T-cell function
in particular, appears to be the most rational approach,
based on the observation of progressive loss of T cells.12,14
Programmed death ligand pathway (eg, PD-1) inhibitors,
such as nivolumab and pembrolizumab, have been game
changers in cancer and some other viral infections.15,16
T cells from patients with COVID-19 show evidence
of T-cell exhaustion associated with increased CD279
(PD-1) expression.11,12
In addition to checkpoint inhibitors, the pluripotent
cytokine IL-7 has been effective in multiple other viral
infections.17–19 Early clinical trials of both treatments have
been initiated in sepsis and shown to be safe and to have
biological activity.20 IL-7 has shown benefit in raising
lymphocyte counts in septic patients with low ALC20 and
in restoring protective immunity in JC virus-induced
progressive multifocal leukoencephalopathy.18,19,21,22 Its
effectiveness, and that of other immune stimulants,
has only begun to be explored in sepsis, and should be
considered in SARS-CoV-2 infection. Although immune
stimulants such as IL-7 or nivolumab could theoretically
feed the cytokine storm, both have been given to
patients with sepsis with IL-6 concentrations similar to
that in patients with COVID-19, without exacerbation of
inflammatory responses.15
Randomised clinical trials based on the best
observational findings remain paramount to moving
forward, and we would propose starting with IL-7.
Because of the complexity of the host response and
the fact that monotherapies have not worked in sepsis
trials in the past, we suggest that priority be given to
biological response modifiers that are pluripotent (such
as IL-7) or combination therapies that target multiple
immunological pathways simultaneously (IL-7 and
anti-PD-1).
What has treating patients with sepsis taught us about
treatment approaches for patients with COVID-19?
Like sepsis, antimicrobials (antivirals in this case) and
supportive therapies are likely to remain the bedrock
of therapeutic interventions for SARS-CoV-2 infection.
However, if SARS-CoV-2 infection is similar to other
chronic inflammatory and immune suppressive diseases,
such as sepsis, we argue that immune stimulants, and
not anti-inflammatory agents, should be considered
as the first-line treatment option. However, we fully
recognise that the pathophysiology and mechanisms
of SARS-CoV-2 are still being elucidated, and that
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there is great uncertainty in predicting the efficacy
of current therapeutic approaches. We are only just
starting to explore the interplay of virus-mediated
endothelial damage, pathogen–receptor signalling
effects (including ACE2), and alterations in haemostasis
and coagulation as a basis for the heterogeneous clinical
pathologies seen in patients. Undeniably, there might be
a subset of patients with exaggerated proinflammatory
cytokine release that could derive benefit from anti-IL-6
or anti-IL-1 therapies. However, until better methods
are available to determine (among the heterogeneity in
clinical phenotypes) which patients meet these criteria,
it will be difficult to establish a benefit. Observations
from clinical centres dealing with large volumes of
patients with COVID-19, show compelling evidence
that patient mortality is directly related to multiorgan
failure, including coagulopathy and probably damage
to the endothelium. These patients also have altered
immune function, as shown by lymphopenia. We suspect
that a balanced, biologically plausible approach would
be to provide anti-inflammatory treatment early in the
disease course coupled with antiviral therapies, such
as remdesivir. However, as the disease transitions to a
suppressed state, therapies that restore host protective
immunity should be considered a high priority for
patients in intensive care with progressing lung injury.
What else needs to be considered? First, better
methods are needed to assess the functional status of
immune cells in patients with COVID-19. Circulating
cytokine concentrations might reflect the degree of
systemic inflammation but are not indicative of the
functional state of individual lymphocyte and myeloid
populations. Readily applicable tests that inform on
whether the adaptive immune system is exhausted or
whether myeloid cells are activated or tolerant would
better guide application of drugs that can appropriately
modulate the immune response. It would also enable
balanced immune therapies targeted to either innate or
adaptive immune cells. This approach is being used in
cancer immunotherapy today and is being tested in the
treatment of sepsis. This balanced therapeutic approach
will allow precise deployment of inhibitory (anti-IL-6 and
anti-IL-1) or restorative (IL-7 and checkpoint inhibitors)
therapies, probably all as adjuvants to antiviral drugs.
Second, we need better measures of viral load with a
rapid turnaround time. We recognise that our ability to
identify and quantitate bacterial infections in patients

with sepsis is still quite rudimentary, and quantifying
viral loads by qPCR has not provided the required
precision, which has hindered our ability to assess the
effectiveness of interventions.
Most importantly, in designing and conducting
interventional trials in patients with COVID-19, we need
to remember the lessons learned from the ongoing
sepsis epidemic that kills 250 000 people annually in
the USA. Inflammation is often transitory, and the
Surviving Sepsis Campaign has shown that earlier
recognition and more immediate implementation of
best practices can reduce early mortality and organ
injury due to the cytokine storm. Conversely, immune
suppression is prolonged, progressive, and ultimately
lethal. Effective treatment of patients in this pandemic
needs to be balanced, to be administered with precision
to individual patients, and to build on our knowledge of
past failures so that we can achieve future successes.
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